HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery - PubMed (original) (raw)
. 2008 May;16(5):893-900.
doi: 10.1038/mt.2008.36. Epub 2008 Mar 11.
Affiliations
- PMID: 18388927
- DOI: 10.1038/mt.2008.36
Free article
HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery
J Andrew MacKay et al. Mol Ther. 2008 May.
Free article
Abstract
We evaluated gene transfer using PEGylated bioresponsive nanolipid particles (NLPs) containing plasmid DNA administered by convection-enhanced delivery (CED) into orthotopically implanted U87-MG tumors in rat brain. We hypothesized that attachment of the human immunodeficiency virus trans-acting transcriptional activator peptide (TATp) to pH-sensitive, reduction-sensitive NLPs would increase gene transfer. TATp was attached either directly to a phospholipid (TATp-lipid) or via a 2-kd polyethylene glycol (PEG) to a lipid (TATp-PEG-lipid). Incorporation of 0.3 mol% TATp-PEG into pH-sensitive NLPs improved transfection 100,000-fold compared to NLPs in culture. In the brain or implanted tumors, the TATp-PEG restricted NLP convection to regions adjacent to the infusion catheter. Gene transfer in the brain from TATp-PEG NLPs, measured by green fluorescent protein (GFP) expression, was substantially greater than from NLPs adjacent to the catheter. Gene transfer using TATp-PEG NLPs, measured by luciferase expression, was 8-12-fold greater than from a 1,2-dioleoyl-3-trimethylammonium-propane/cholesterol cationic lipoplex but 13-27-fold less than from the NLPs. Brain luciferase expression was localized in perivascular macrophages. Thus a cationic ligand, such as the TATp-PEG-lipid, can dramatically increase gene expression in culture, in the normal brain, and in implanted tumors; however, restriction of NLP distribution to the vicinity of the infusion catheter reduces the absolute level of gene transfer.
Similar articles
- TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice.
Gupta B, Levchenko TS, Torchilin VP. Gupta B, et al. Oncol Res. 2007;16(8):351-9. doi: 10.3727/000000006783980946. Oncol Res. 2007. PMID: 17913043 - Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes.
Kale AA, Torchilin VP. Kale AA, et al. J Drug Target. 2007 Aug-Sep;15(7-8):538-45. doi: 10.1080/10611860701498203. J Drug Target. 2007. PMID: 17671900 Free PMC article. - Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems.
Rezaee M, Oskuee RK, Nassirli H, Malaekeh-Nikouei B. Rezaee M, et al. J Control Release. 2016 Aug 28;236:1-14. doi: 10.1016/j.jconrel.2016.06.023. Epub 2016 Jun 15. J Control Release. 2016. PMID: 27317365 Review. - Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery.
Torchilin VP. Torchilin VP. Biopolymers. 2008;90(5):604-10. doi: 10.1002/bip.20989. Biopolymers. 2008. PMID: 18381624 Review.
Cited by
- Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain.
Mastorakos P, Zhang C, Berry S, Oh Y, Lee S, Eberhart CG, Woodworth GF, Suk JS, Hanes J. Mastorakos P, et al. Adv Healthc Mater. 2015 May;4(7):1023-33. doi: 10.1002/adhm.201400800. Epub 2015 Mar 11. Adv Healthc Mater. 2015. PMID: 25761435 Free PMC article. - Convection-enhanced delivery for the treatment of brain tumors.
Debinski W, Tatter SB. Debinski W, et al. Expert Rev Neurother. 2009 Oct;9(10):1519-27. doi: 10.1586/ern.09.99. Expert Rev Neurother. 2009. PMID: 19831841 Free PMC article. Review. - Environmentally responsive peptides as anticancer drug carriers.
Aluri S, Janib SM, Mackay JA. Aluri S, et al. Adv Drug Deliv Rev. 2009 Sep 30;61(11):940-52. doi: 10.1016/j.addr.2009.07.002. Epub 2009 Jul 20. Adv Drug Deliv Rev. 2009. PMID: 19628014 Free PMC article. Review. - Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain.
Mastorakos P, Song E, Zhang C, Berry S, Park HW, Kim YE, Park JS, Lee S, Suk JS, Hanes J. Mastorakos P, et al. Small. 2016 Feb 3;12(5):678-85. doi: 10.1002/smll.201502554. Epub 2015 Dec 17. Small. 2016. PMID: 26680637 Free PMC article. - Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A, Koren E, Koshkaryev A, Torchilin VP. Apte A, et al. Cancer Biol Ther. 2014 Jan;15(1):69-80. doi: 10.4161/cbt.26609. Epub 2013 Oct 21. Cancer Biol Ther. 2014. PMID: 24145298 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- 8R01EB002047/EB/NIBIB NIH HHS/United States
- R01CA107268/CA/NCI NIH HHS/United States
- NS42927/NS/NINDS NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R01 CA107268/CA/NCI NIH HHS/United States
- CA-85356/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources